Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–331 of 331 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pelvic Malignancies Clear all

Conditions: Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: bortezomib; Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 11
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions: cisplatin, tirapazamine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 273
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 195 more

Conditions: Prostate Adenocarcinoma
Interventions: C-11 choline PET tracer, Gadobutrol, PET/MR scanner; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, Biospecimen Collection, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: 99mTc-MIP-1404; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Radiation; Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uterine Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cervical Cancer, Vulvar Cancer
Interventions: Survey; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 20 Years and older · Female only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma
Interventions: Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ureteral Obstruction
Interventions: Memokath 051 Ureteral Stent, JJ Stent; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cervical Cancer
Interventions: carboplatin, cisplatin, paclitaxel, intensity-modulated radiation therapy, standard external beam radiation therapy, Optional brachytherapy boost; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 98 more

Conditions: Adnexal Mass, Ovarian Cancer, Pelvic Mass
Interventions: Not listed
Lead sponsor: Venn Biosciences Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,025 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • San Jose, California • Sunnyvale, California + 7 more

Conditions: Ovarian Neoplasms
Interventions: Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision; Procedure
Lead sponsor: Angle plc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Prostate Cancer, Pelvic Pain, Incontinence
Interventions: Radical Prostatectomy, InterStim Implantation, Pelvic organ prolapse repair; Procedure
Lead sponsor: Kenneth Peters, MD; Other
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Cervical Cancer
Interventions: Topotecan, Cisplatin; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Orange, California

Conditions: Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms, Thoracic Neoplasms
Interventions: Sunitinib, External Beam Radiation Therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Cancer
Interventions: therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more

Conditions: Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor, Kidney Injury
Interventions: RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 22 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 6
States / cities: Duarte, California • Chicago, Illinois • New York, New York + 3 more

Search by objective public record fields.

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Hypofractionated WPPT With HDR Boost

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Intensity Modulated Radiation Therapy for Prostate Cancer

Pelvic Floor Disorders in Survivors of Gynecologic Malignancies

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy

Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.

Urology Database for Outcomes Research

Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)